Sino-orbital mucormycosis in a COVID-19 patient: A case report

This article was originally published here

Int J Surg Case Rep. 2021 May 4;82:105957. doi: 10.1016/j.ijscr.2021.105957. Online ahead of print.

ABSTRACT

INTRODUCTION: We report a case of post COVID-19 Sino-orbital Mucormycosis infection caused by Rhizopus oryzae and its management.

PRESENTATION OF CASE: The patient was diagnosed with COVID-19 and treated according to the persisting protocols. Following recovery, on the 18th day, the patient developed chemosis and pain in the left eye. A diagnosis of mucormycosis was established after Magnetic Resonance Imaging (MRI) and Functional Endoscopic Sinus Surgery (FESS). Initially, conservative management with intravenous (IV) Fluconazole & Amphotericin B was done and later on with surgical debridement. The patient recovered with minimal residual deformity.

DISCUSSION: Mucormycosis generally develops secondary to immunosuppression or debilitating diseases. In Head and Neck cases, the mold usually gains entry through the respiratory tract involving the nose and sinuses, with possible further progression into the orbital and intracranial structures. Hence, an early diagnosis and intervention is required for a good prognosis, decreasing the morbidity. This can be achieved on the basis of clinical picture and direct smears.

CONCLUSION: Research needs to be carried out in COVID-19 patients for better prevention and management of opportunistic infections in order to reduce its incidence and morbidity. Prophylactic treatment protocols need to be established, along with rational use of corticosteroids.

PMID:33964720 | DOI:10.1016/j.ijscr.2021.105957